Clarity

Clarity is developing OSMOSIS, a prescription at-home treatment for Alzheimer's and MS that delivers clinically proven 40Hz gamma stimulation inside personalized immersive experiences — family videos, streamed media, and adaptive cognitive tasks — for just 30 minutes a day. Unlike existing drugs, OSMOSIS works non-invasively, with no serious adverse events, and is designed for broad patient access. Each session generates neural-behavioral data that trains proprietary brain foundation models, creating a compounding data moat. Targeting FDA 510(k) clearance and commercial launch in 2028, the company addresses a $24B+ annual US market opportunity in Alzheimer's alone. The team brings experience from UC Berkeley, Oxford, Tesla and Meta, is supported by 8+ patent families, 2 clinical programs, top research and clinical partners (e.g., UCSF), and investors including a16z and index scout funds.

Neurodegenerative diseases like Alzheimer's affect 80M patients globally today, projected to reach 180M by 2050 at a total cost of $13 trillion. Current FDA-approved treatments (anti-amyloid drugs) offer limited efficacy (<27% reduction in cognitive decline), have serious adverse events in 21% of patients, cost $26,500+/year, and fewer than 17% of patients qualify.

Clarity's OSMOSIS platform delivers 40Hz gamma sensory stimulation via VR/AR headsets embedded with eye-tracking, voice, and biosensors — proven to reduce neuroinflammation, increase neuroplasticity, and drive glymphatic clearance. The adaptive AI software personalizes stimulation within engaging content (personal memories, Netflix, disease-relevant cognitive tasks), requiring only 30 minutes/day, and collects multimodal neural-behavioral data to continuously improve treatment and build brain foundation models.

Clarity has raised $3M from 30+ investors (strategics, VCs and angels from Netflix, Sanofi and Meta), filed 8+ patent families, published one peer-reviewed scientific paper (healthy elders) and has a second under review (mild AD patients). A 27-participant in-clinic Alzheimer's study (NCT06234930) is completed, a 30-patient MS RCT (NCT07310862) is ongoing in Barcelona, and a 250k+ patient pipeline is in place through strategic partnerships in France, Spain, and Australia. An LOI has been signed with a leading wearable/XR OEM for manufacturing.